Bronnen en verantwoording

Cass H. — Independent Review of Gender Identity Services for Children and Young People: Final Report. NHS England, april 2024. De meest uitgebreide onafhankelijke evaluatie van kindergenderzorg in een Westers land tot nu toe.

York University Systematic Reviews — Acht systematische reviews uitgevoerd in opdracht van de Cass Review, gepubliceerd in Archives of Disease in Childhood, 2024. Behandelen evidence-base voor puberty blockers, cross-sex hormones, psychosociale uitkomsten en internationale richtlijnen.

NICE — Evidence review: Gonadotrophin releasing hormone analogues for children and adolescents with gender dysphoria. NHS England, oktober 2020. Evidence-beoordeling 'very low certainty' (GRADE).

NICE — Evidence review: Gender-affirming hormones for children and adolescents with gender dysphoria. NHS England, oktober 2020.

COHERE (Finland) — Recommendation on medical treatment methods for dysphoria related to gender variance in minors. Council for Choices in Health Care in Finland, juni 2020.

Socialstyrelsen (Zweden) — Care of children and adolescents with gender dysphoria: updated knowledge support. februari 2022.

Sundhedsstyrelsen (Denemarken) — National clinical guideline on the treatment of gender dysphoria in children and young people. 2023.

Cohen-Kettenis P.T., van Goozen S.H. — Pubertal delay as an aid in diagnosis and treatment of a transsexual adolescent. European Child & Adolescent Psychiatry, 1998. Eerste gepubliceerde casuïstiek.

Delemarre-van de Waal H.A., Cohen-Kettenis P.T. — Clinical management of gender identity disorder in adolescents: a protocol on psychological and paediatric endocrinology aspects. European Journal of Endocrinology, 2006.

de Vries A.L.C., Steensma T.D., Doreleijers T.A., Cohen-Kettenis P.T. — Puberty suppression in adolescents with gender identity disorder: A prospective follow-up study. Journal of Sexual Medicine, 2011.

de Vries A.L.C., McGuire J.K., Steensma T.D., Wagenaar E.C., Doreleijers T.A., Cohen-Kettenis P.T. — Young adult psychological outcome after puberty suppression and gender reassignment. Pediatrics, 2014.

Klink D., Caris M., Heijboer A., van Trotsenburg M., Rotteveel J. — Bone mass in young adulthood following GnRH-analog treatment and cross-sex hormone treatment in adolescents with gender dysphoria. JCEM, 2015.

Schagen S.E.E. et al. — Bone Development in Transgender Adolescents Treated With GnRH Analogues and Subsequent Gender-Affirming Hormones. JCEM, 2020.

Staphorsius A.S. et al. — Puberty suppression and executive functioning: An fMRI study in adolescents with gender dysphoria. Psychoneuroendocrinology, 2015.

Biggs M. — The Dutch Protocol for Juvenile Transsexuals: Origins and Evidence. Journal of Sex & Marital Therapy, 2022. Uitvoerige heranalyse, wijst op afwezigheid controlegroep, selectiebias en interpretatieproblemen.

Levine S.B., Abbruzzese E., Mason J.W. — Reconsidering Informed Consent for Trans-Identified Children, Adolescents, and Young Adults. Journal of Sex & Marital Therapy, 2022.

Levine S.B., Abbruzzese E. — Current Concerns About Gender-Affirming Therapy in Adolescents. Current Sexual Health Reports, 2023.

Hunter P. — A Critical Examination of the Dutch Protocol. Society, 2023.

Block J. — Gender dysphoria in young people is rising — and so is professional disagreement. BMJ, 380:p382, februari 2023.

Abbruzzese E., Levine S.B., Mason J.W. — The Myth of "Reliable Research" in Pediatric Gender Medicine. Journal of Sex & Marital Therapy, 2023.

Hembree W.C. et al. — Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline. JCEM, 2017.

WPATH — Standards of Care for the Health of Transgender and Gender Diverse People, Version 8. World Professional Association for Transgender Health, 2022.

KNMG — Handreiking 'Off-label voorschrijven van geneesmiddelen', laatste versie via knmg.nl.

EMA — Summary of Product Characteristics: triptoreline (Decapeptyl), leuproreline (Lucrin), gosereline (Zoladex). Officiële registratie-indicaties.

Carmichael P. et al. — Short-term outcomes of pubertal suppression in a selected cohort of 12 to 15 year old young people with persistent gender dysphoria in the UK. PLOS ONE, 2021. Heranalyse Tavistock-cohort.

Hough D. et al. — A reduction in long-term spatial memory persists after discontinuation of peripubertal GnRH agonist treatment in sheep. Psychoneuroendocrinology, 2017.

Cheng P.J. et al. — Fertility concerns of the transgender patient. Translational Andrology and Urology, 2019.

Nahata L., Tishelman A.C., Caltabellotta N.M., Quinn G.P. — Low Fertility Preservation Utilization Among Transgender Youth. Journal of Adolescent Health, 2017.

Kaltiala R., Heino E., Työläjärvi M., Suomalainen L. — Adolescent development and psychosocial functioning after starting cross-sex hormones for gender dysphoria. Nordic Journal of Psychiatry, 2020.

Conn P.M., Crowley W.F. — Gonadotropin-releasing hormone and its analogues. New England Journal of Medicine, 1991. Klassiek farmacologisch overzicht.

Sisk C.L., Foster D.L. — The neural basis of puberty and adolescence. Nature Neuroscience, 2004. Theoretisch kader.

Bell v. Tavistock and Portman NHS Foundation Trust, [2020] EWHC 3274 (Admin). Hoger beroep: [2021] EWCA Civ 1363. Sleuteluitspraak over Gillick-competentie van minderjarigen ten aanzien van puberty blockers.

United States v. Skrmetti, 605 U.S. _ (2025). US Supreme Court oordeel over wettelijke beperking medische transitie minderjarigen door deelstaten.

de Vries A.L.C. — Commentary on Cass Review. JAMA Pediatrics, 2024.

ZonMw — Evaluatie jeugd-genderzorg Nederland, toegekend programma 2024 (eerste rapportage verwacht 2026).

Tweede Kamer der Staten-Generaal — Kamerdebatten en moties over jeugd-genderzorg, 2024. Te raadplegen via tweedekamer.nl.

Begeer S. et al. — Aanmeldingen en behandelresultaten Nederlands genderzorg-cohort. Diverse publicaties Vrije Universiteit Amsterdam, 2022-2024.

Genspect NL en TransSpijt — Documentatie detrans-getuigenissen en zorgen ouders, 2023-2025.